Skip to main content

Table 1 Unadjusted associations for mortality or post-infection length of stay among patients with MRSA pneumonia

From: Association between microbial characteristics and poor outcomes among patients with methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study

  Proportion of patients with characteristic 30-Day-In-Hospital mortalitya Post-infection length of stayb
Characteristics Patients who died N = 18 Patients who survived N = 57 Hazards ratio (95 % Confidence Interval) P-value Odds ratio (95 % Confidence Interval) P-value
Patient characteristics
 Gender: Female 9 (50 %) 20 (35 %) 1.81 (0.72–4.57) 0.201 1.44 (0.63–3.30) 0.385
 Age ≥55 years    4.69 (1.36–16.22) 0.015 2.15 (0.95–4.87) 0.068
 Hospital admission within previous 12 months 6 (33 %) 31 (54 %) 0.52 (0.19–1.37) 0.185 0.40 (0.17–0.91) 0.028
 Previous MRSA infection or colonization 6 (33 %) 11 (19 %) 1.82 (0.68–4.88) 0.234 1.31 (0.50–3.42) 0.583
 Positive influenza test 2 (11 %) 3 (5 %) 1.69 (0.39–7.38) 0.488 2.13 (0.41–11.01) 0.368
 Charlson comorbidity index score- median (IQR) 2 (1–3) 2 (1–4) 0.99 (0.83–1.20) 0.948 0.99 (0.84–1.16) 0.896
Hospital-acquired infection 6 (33 %) 19 (33 %) 0.85 (0.32–2.29) 0.752 1.50 (0.64–3.53) 0.354
Antimicrobial prescribed
 Linezolid 2 (11 %) 12 (21 %) 0.60 (0.14–2.60) 0.492 0.36 (0.13–1.03) 0.056
 Vancomycin 17 (94 %) 54 (95 %) 0.61 (0.08–4.68) 0.223 3.10 (0.51–19.02) 0.221
 Both linezolid and vancomycin 1 (6 %) 9 (16 %) 0.37 (0.05–2.76) 0.331 0.43 (0.13–1.41) 0.162
Microbial characteristics
 Panton-Valentine leukocidin 5 (28 %) 24 (42 %) 0.82 (0.36–1.88) 0.645 0.82 (0.36–1.88) 0.645
 SCCmec
  Type II 12 (67 %) 27 (47 %) 1.22 (0.54–2.72) 0.634 1.22 (0.54–2.72) 0.634
  Type IV 6 (33 %) 29 (51 %) 0.79 (0.35–1.76) 0.555 0.79 (0.35–1.76) 0.555
agr dysfunction 4 (22 %) 9 (16 %) 1.35 (0.44–4.10) 0.598 1.59 (0.54–4.62) 0.399
 Arginine catabolic mobile element 3 (17 %) 22 (39 %) 0.35 (0.10–1.20) 0.094 0.70 (0.30–1.64) 0.413
 Toxic shock syndrome toxin-1 1 (6 %) 2 (4 %) 1.22 (0.16–9.19) 0.846 2.35 (0.29–19.27) 0.423
 PFGE type
  USA100 11 (61 %) 25 (44 %) 1.87 (0.72–4.82) 0.197 1.20 (0.54–2.69) 0.652
  USA300 4 (22 %) 25 (44 %) 0.40 (0.13–1.21) 0.104 0.66 (0.29–1.51) 0.323
  Other 3 (17 %) 7 (12 %) 1.40 (0.41–4.85) 0.594 1.57 (0.48–5.16) 0.458
  1. IQR interquartile range, SCCmec staphylococcal cassette chromosome mec, agr accessory gene regulator, PFGE pulsed-field gel electrophoresis, hVISA heterogeneous vancomycin-intermediate S. aureus
  2. aDefined as death occurring within the first 30 days after the day when the first MRSA positive respiratory or blood culture was collected
  3. bDefined as the day the first MRSA positive respiratory or blood culture was collected until the day the patient was either discharged from the hospital or died